UNSPSC 51373405: Ammonium chloride/chlorpheniramine/codeine/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373405 Ammonium chloride/chlorpheniramine/codeine/phenylephrine is a Commodity code, but the recent state and local opportunities posted under it show little alignment with its nominal scope — the two opportunities solicited are naloxone and safe drug deactivation systems (Seminole County, Florida) and generic multi-source pharmaceuticals and OTC products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). Neither solicitation specifically targets the combination antihistamine-decongestant-antitussive product named in the code. State and local procurement offices appear to be using this code as a catch-all for pharmaceutical acquisitions that do not fit more precisely defined commodity categories, or the tagging reflects internal system classification rather than the actual products being purchased. The issuing bodies include county health departments and multi-state cooperative purchasing alliances administering programs on behalf of state and local members across multiple jurisdictions.

The two recent opportunities span Florida and a multi-state vehicle anchored in Minnesota and including Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract includes a two-year initial term with a one-year renewal option and is potentially FEMA-funded. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities; vendors must supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson), comply with cGMP and DSCSA, and maintain pricing flexibility with scoring weighted 75 percent on price competitiveness. The code shows activity but limited relevance to its stated pharmaceutical combination.